Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine

Liang, Huabin; Lee, Min; Jin, Xia

doi:10.1038/cmi.2015.76

Cited by 23 publications

(23 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As these agents have nonhuman reservoirs, an achievable goal is effective control of the spread of infection via prophylactic, or pre-exposure vaccination. The mature virion of all flaviviruses consists of an icosahedral particle with three structural proteins: capsid, membrane, and envelope [7]. The primary target of neutralizing antibodies induced by flavivirus vaccines is the envelope protein, although antibodies against the membrane protein and a nonstructural protein, NS1, have also been shown to be protective [8].…”

Section: Vaccines Available Against Zoonotic Flavivirusesmentioning

confidence: 99%

“…Yellow fever is also associated with encephalitis and myelitis [16]. Approximately 200,000 cases of YF occur annually, leading to 60,000 deaths worldwide [7,17]. Transmission occurs through Aedes aegypti mosquitos.…”

Section: Yellow Fever Virusmentioning

confidence: 99%

“…The currently available vaccine, YF-17D, has been administered to more than 600 million people worldwide and is live attenuated, developed by successive passages of the Asibi viral strain in mouse and chicken embryos [7]. A single dose should confer lifelong protective immunity [18], which is reflected by the vaccine's strong immune signature; notably, the efficient activation of antigen presenting cells, high neutralizing antibody titers, the induction of polyfunctional T cells, and long-term memory T and B cells [7].…”

Section: Yellow Fever Virusmentioning

confidence: 99%

“…A single dose should confer lifelong protective immunity [18], which is reflected by the vaccine's strong immune signature; notably, the efficient activation of antigen presenting cells, high neutralizing antibody titers, the induction of polyfunctional T cells, and long-term memory T and B cells [7]. A robust type I interferon response can be transiently observed in the blood transcriptomes of vaccinated individuals [19].…”

Section: Yellow Fever Virusmentioning

confidence: 99%

“…Patients who are sequentially infected by multiple DENV serotypes are more likely to manifest severe symptoms, which is thought to be attributable to the mechanism of antibody-dependent enhancement. Therefore, a safe and effective dengue vaccine must be multivalent to induce robust homotypic immunity to each of the four serotypes [7,24].…”

Section: Dengue Virusmentioning

confidence: 99%

See 4 more Smart Citations

Vaccinations for Neuroinfectious Disease: A Global Health Priority

Leibovitch

Jacobson

2016

Neurotherapeutics

View full text Add to dashboard Cite

Vaccines for neuroinfectious diseases are becoming an ever-increasing global health priority, as neurologic manifestations and sequelae from existing and emerging central nervous system infections account for significant worldwide morbidity and mortality. The prevention of neurotropic infections can be achieved through globally coordinated vaccination campaigns, which have successfully eradicated nonzoonotic agents such as the variola viruses and, hopefully soon, poliovirus. This review discusses vaccines that are currently available or under development for zoonotic flaviviruses and alphaviruses, including Japanese and tick-borne encephalitis, yellow fever, West Nile, dengue, Zika, encephalitic equine viruses, and chikungunya. Also discussed are nonzoonotic agents, including measles and human herpesviruses, as well as select bacterial, fungal, and protozoal pathogens. While therapeutic vaccines will be required to treat a multitude of ongoing infections of the nervous system, the ideal vaccination strategy is preexposure vaccination, with the ultimate goals of minimizing disease associated with zoonotic viruses and the total eradication of nonzoonotic agents.

show abstract

Section: Vaccines Available Against Zoonotic Flavivirusesmentioning

confidence: 99%

Section: Yellow Fever Virusmentioning

confidence: 99%

Section: Yellow Fever Virusmentioning

confidence: 99%

Section: Yellow Fever Virusmentioning

confidence: 99%

Section: Dengue Virusmentioning

confidence: 99%

See 3 more Smart Citations

Vaccinations for Neuroinfectious Disease: A Global Health Priority

Leibovitch

Jacobson

2016

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

Preventive and therapeutic challenges in combating Zika virus infection: are we getting any closer?

et al. 2017

View full text Add to dashboard Cite

The neuroteratogenic nature of Zika Virus (ZIKV) infection has converted what would have been a tropical disease into a global threat. Zika is transmitted vertically via infected placental cells especially in the first and second trimesters. In the developing central nervous system (CNS), ZIKV can infect and induce apoptosis of neural progenitor cells subsequently causing microcephaly as well as other neuronal complications in infants. Its ability to infect multiple cell types (placental, dermal, and neural) and increased environmental stability as compared to other flaviviruses (FVs) has broadened the transmission routes for ZIKV infection from vector-mediated to transmitted via body fluids. To further complicate the matters, it is genetically similar (about 40%) with the four serotypes of dengue virus (DENV), so much so that it can almost be called a fifth DENV serotype. This homology poses the risk of causing cross-reactive immune responses and subsequent antibody-dependent enhancement (ADE) of infection in case of secondary infections or for immunized individuals. All of these factors complicate the development of a single preventive vaccine candidate or a pharmacological intervention that will completely eliminate or cure ZIKV infection. We discuss all of these factors in detail in this review and conclude that a combinatorial approach including immunization and treatment might prove to be the winning strategy.

show abstract